HRD

IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705)

Retrieved on: 
星期一, 八月 21, 2023
Theta, GSK, DNA, Therapy, Neoplasm, HRD, POLQ, Cancer, Research, MMEJ, DNA polymerase, Investigational New Drug, Patient, Homologous recombination, Medicine, HR, BRCA, FDA, PARP, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, DNA repair, Pharmaceutical industry, IND

We are also targeting the Werner Helicase development candidate nomination later this year with GSK, which represents our fifth potential first-in-class program," said Yujiro S. Hata, Chief Executive Officer, IDEAYA Biosciences.

Key Points: 
  • We are also targeting the Werner Helicase development candidate nomination later this year with GSK, which represents our fifth potential first-in-class program," said Yujiro S. Hata, Chief Executive Officer, IDEAYA Biosciences.
  • GSK101 is a potential first-in-class small molecule inhibitor of the helicase domain of DNA Polymerase Theta (Pol Theta).
  • The Pol Theta enzyme facilitates DNA repair through microhomology-mediated end joining (MMEJ), an enzymatic function that enables reversion of BRCA mutations.
  • GSK will lead clinical development for the Pol Theta program pursuant to its global, exclusive license to develop and commercialize the Pol Theta Helicase Inhibitor DC (GSK Pol Theta License).

Canada doubles resettlement spaces for human rights defenders

Retrieved on: 
星期二, 七月 25, 2023
Rainbow Railroad, Exercise, Refugee, Filippo Grandi, Partnership, Violence, HRD, Prosperity, Woman, Human, IRCC, Immigration, Refugees and Citizenship Canada, Persecution, United Nations High Commissioner for Refugees, Torture, Detention (imprisonment), Risk, Government of Canada, Environment, Drug, Citizenship

OTTAWA, ON, July 25, 2023 /CNW/ - Human rights defenders (HRDs) are active in every part of the world and play an essential role in promoting and protecting human rights internationally.

Key Points: 
  • OTTAWA, ON, July 25, 2023 /CNW/ - Human rights defenders (HRDs) are active in every part of the world and play an essential role in promoting and protecting human rights internationally.
  • The Honourable Sean Fraser, Minister of Immigration, Refugees and Citizenship, today announced the expansion of the global human rights defenders stream, doubling the number of resettlement spaces from 250 to 500 for HRDs and their family members.
  • Human rights defenders help build the inclusive and democratic societies that contribute to a peaceful and prosperous international community.
  • As the world grapples with numerous human rights challenges, Canada is reinforcing its role as a global leader in promoting human rights and protecting those who safeguard them.

SOPHiA GENETICS Announces Gruppo Centro Servizi Medici (CSM) is Live on the SOPHiA DDM™ Platform

Retrieved on: 
星期四, 七月 13, 2023
Workflow, HRD, NGS, Cancer, Research, Sophia, Laboratory, GENETICS, CSM, Artificial intelligence

BOSTON and ROLLE, Switzerland, July 13, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Gruppo Centro Servizi Medici (CSM), one of the largest centralized laboratories in Italy, is live on SOPHiA GENETICS technology. CSM has implemented the SOPHiA DDM™ Platform to help expand its current next-generation sequencing (NGS) offerings and advance its research of hereditary cancer and homologous recombination deficiency (HRD).

Key Points: 
  • BOSTON and ROLLE, Switzerland, July 13, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Gruppo Centro Servizi Medici (CSM), one of the largest centralized laboratories in Italy, is live on SOPHiA GENETICS technology.
  • The SOPHiA DDM™ Platform is a cloud-based platform that uses Artificial Intelligence (AI) with patented technologies to analyze and interpret NGS data.
  • With the SOPHiA GENETICS technology, CSM will have in-house ownership of their genomic databases shared across their access points.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on Twitter , LinkedIn , Facebook , and Instagram .

ECO Canada awarded HRD Canada’s Best Places to Work 2023

Retrieved on: 
星期三, 六月 21, 2023
Workforce, European Economic and Social Committee, HRD, Reward, Statistics, ECO Canada, Research, Organization, Student, Work, ECO, HR, Health, Family, Management

CALGARY, Alberta, June 21, 2023 (GLOBE NEWSWIRE) -- ECO Canada has been awarded HRD Canada’s Best Places to Work 2023 .

Key Points: 
  • CALGARY, Alberta, June 21, 2023 (GLOBE NEWSWIRE) -- ECO Canada has been awarded HRD Canada’s Best Places to Work 2023 .
  • ECO Canada aims to promote and drive responsible, sustainable economic growth while also ensuring that environmental best practices remain a priority.
  • The entry process for HRD Canada’s Best Places to Work ranking comprised two steps: an employer submission followed by an employee survey.
  • ECO Canada also prioritizes a flexible work environment, with a hybrid schedule giving employees the option to work two days a week from home.

NOMAD Genetics is Live on the SOPHiA GENETICS Platform

Retrieved on: 
星期四, 六月 15, 2023
DNA, Specialization, HRR, Sophia Genetics, Workflow, HRD, Deep learning, Breast, Research, Genomics, Prostate, Doctor of Philosophy, Sophia, Genetics, Laboratory, Algorithm, GENETICS, Medicine, Cancer, NOMAD, Health, LATAM, Agriculture, Vaccine, Advertising

BOSTON and LAUSANNE, Switzerland, June 15, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced a strategic alliance with NOMAD Genetics. Headquartered in Mexico City and Chile, NOMAD is an innovative laboratory renowned for its specialization in genomics and clinical research. Through the seamless deployment of SOPHiA GENETICS' trailblazing SOPHiA DDM™ Platform, NOMAD Genetics is augmenting its research capabilities while elevating its operational efficiency.

Key Points: 
  • Through the seamless deployment of SOPHiA GENETICS' trailblazing SOPHiA DDM™ Platform, NOMAD Genetics is augmenting its research capabilities while elevating its operational efficiency.
  • With the SOPHiA GENETICS Platform, laboratories like NOMAD Genetics can quickly obtain interpreted results, creating increased efficiencies for clinical researchers.
  • In addition, SOPHiA GENETICS allows NOMAD Genetics to retain full ownership of their data, saving time and expense, while offering comprehensive genomic insights powered by deep learning algorithms.
  • "Our products and solutions are designed to enable facilities like NOMAD Genetics to more easily advance precision-medicine," said Ricardo Mendonca Filho, PhD, Managing Director, LAPAC, SOPHiA GENETICS.

Bionano Announces Commercial Release of New Kits for its Ionic System featuring New Chemistry for Nucleic Acid Extraction from FFPE and Tumor Tissue

Retrieved on: 
星期二, 六月 6, 2023
Tissue, DNA, G2, HRD, Genomics, NGS, ITP, RNA, Doctor of Philosophy, Isotachophoresis, Chemistry, Dicarboxylic acid, SAN, UHMW, OGM, Ionic, Phosphorus

SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the commercial release of new kits for its Ionic® Purification System featuring new chemistry for nucleic acid extraction from formalin-fixed paraffin-embedded (FFPE) and tumor tissue.

Key Points: 
  • SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the commercial release of new kits for its Ionic® Purification System featuring new chemistry for nucleic acid extraction from formalin-fixed paraffin-embedded (FFPE) and tumor tissue.
  • Most clinical samples used in oncology research are stored as FFPE tissues, which often contain degraded or fragmented nucleic acid.
  • Conventional extraction methods are labor intensive and can further damage nucleic acid during the extraction and purification process.
  • The Ionic® G2 chemistry includes four new kits for use with the Ionic Purification System, including G2 FFPE to DNA, G2 FFPE to RNA, G2 FFPE Complete and G2 Tissue to DNA.

Caris Life Sciences and ConcertAI Expand Partnership to Create First-in-Class, Prospectively Matched Clinico-Genomic Research Platform

Retrieved on: 
星期四, 六月 1, 2023
Database, Partnership, TMB, Sequence, Royal IHC, HRD, Cancer, Deletion, MBA, Research, H&E, Organization, Patient, Collection, MSI, WSI, Medicine, Hematology, Artificial intelligence, AI, WES, Health, GLOH, Medical imaging, Pharmaceutical industry

IRVING, Texas and CAMBRIDGE, Mass., June 1, 2023  /PRNewswire/ --Caris Life Sciences®(Caris), the leading molecular science, artificial intelligence (AI) and machine learning technology company actively developing and delivering innovative solutions to revolutionize healthcare, and ConcertAI, the leading oncology real-world evidence data and AI technology company, today announced an expanded translational sciences and clinical development solutions partnership.  In the coming months, Caris and ConcertAI will create a prospectively generated, EHR-enabled and contemporaneously matched database of molecular, clinical and multi-modal data that will enable novel insights for precision medicine, therapeutic development and clinical trials management for academic and biopharma researchers.

Key Points: 
  • In the coming months, Caris and ConcertAI will create a prospectively generated, EHR-enabled and contemporaneously matched database of molecular, clinical and multi-modal data that will enable novel insights for precision medicine, therapeutic development and clinical trials management for academic and biopharma researchers.
  • Building upon the successful January 2023 agreement, this expanded collaboration establishes the gold standard of multi-modal data by leveraging Caris' and ConcertAI's respective best-in-class molecular, clinical and multi-modal data to create the largest-scale oncology research platform in the industry.
  • "The future of cancer care will be driven by massive amounts of comprehensive biological and clinical data.
  • The company's Patient360™ specification has emerged as the reference standard for leading biopharma and other research groups.

Caris Life Sciences and ConcertAI Expand Partnership to Create First-in-Class, Prospectively Matched Clinico-Genomic Research Platform

Retrieved on: 
星期四, 六月 1, 2023
Database, Partnership, TMB, Sequence, Royal IHC, HRD, Cancer, Deletion, MBA, Research, H&E, Organization, Patient, Collection, MSI, WSI, Medicine, Hematology, Artificial intelligence, AI, WES, Health, GLOH, Medical imaging, Pharmaceutical industry

IRVING, Texas and CAMBRIDGE, Mass., June 1, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science, artificial intelligence (AI) and machine learning technology company actively developing and delivering innovative solutions to revolutionize healthcare, and ConcertAI, the leading oncology real-world evidence data and AI technology company, today announced an expanded translational sciences and clinical development solutions partnership. In the coming months, Caris and ConcertAI will create a prospectively generated, EHR-enabled and contemporaneously matched database of molecular, clinical and multi-modal data that will enable novel insights for precision medicine, therapeutic development and clinical trials management for academic and biopharma researchers.

Key Points: 
  • In the coming months, Caris and ConcertAI will create a prospectively generated, EHR-enabled and contemporaneously matched database of molecular, clinical and multi-modal data that will enable novel insights for precision medicine, therapeutic development and clinical trials management for academic and biopharma researchers.
  • Building upon the successful January 2023 agreement, this expanded collaboration establishes the gold standard of multi-modal data by leveraging Caris' and ConcertAI's respective best-in-class molecular, clinical and multi-modal data to create the largest-scale oncology research platform in the industry.
  • "The future of cancer care will be driven by massive amounts of comprehensive biological and clinical data.
  • The company's Patient360™ specification has emerged as the reference standard for leading biopharma and other research groups.

Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting

Retrieved on: 
星期三, 五月 31, 2023
Health Technology, Health, Oncology, Medical Devices, FGFR, DNA, Nucleic acid thermodynamics, HER2, ESR1, HRD, Survival, Tiffany, Mutation, TKI, Research, ERBB2, NSCLC, GH, ASCO, Helmy Eltoukhy, DNA repair, Patient, Manhattan Center, Annual general meeting, Neoplasm, FDA, Tumor microenvironment, Society, American Society of Clinical Oncology, Safety, Breast cancer, Medical imaging, Vaccine

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the company and its research collaborators will present data from 17 studies that highlight the contribution of Guardant blood tests and real-world data to advances in precision oncology and cancer screening at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting, June 2-6 in Chicago.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the company and its research collaborators will present data from 17 studies that highlight the contribution of Guardant blood tests and real-world data to advances in precision oncology and cancer screening at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting, June 2-6 in Chicago.
  • “We look forward to sharing new data at ASCO that demonstrate scientific and clinical advances across the entire continuum of cancer care,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO.
  • (Abstract 556, Sunday, June 4, 8-11am, Hall A)
    Guardant Health collaborators will present a session on the ESR1 mutational landscape and the impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.
  • The study also explores additional co-mutations ascertained through broad genomic liquid profiling and their impact on patient survival.

Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer

Retrieved on: 
星期三, 五月 24, 2023
Folate, Workflow, HRD, UC San Diego School of Medicine, MYGN, National Comprehensive Cancer Network, SALT, Genetics, Journal of the National Comprehensive Cancer Network, Patient, Reproductive Sciences, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Medicine, Genetic testing, MIRV, Neoplasm, Oncology, FDA, Ovarian cancer, Myriad Genetics, Myriad, Medical imaging, Obstetrics, Gynaecology

SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha (FRα) to its Precise™ Oncology Solutions portfolio. The new biomarker adds another companion diagnostic option for providers to help guide treatment decisions for patients with ovarian cancer.

Key Points: 
  • SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha (FRα) to its Precise™ Oncology Solutions portfolio.
  • The new biomarker adds another companion diagnostic option for providers to help guide treatment decisions for patients with ovarian cancer.
  • FRα is a biomarker commonly expressed in patients with ovarian cancer.
  • FRα is a newly recommended biomarker test included in the National Comprehensive Cancer Network treatment guidelines for ovarian cancer.